pioneer 8 semaglutide Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes? Summary of PIONEER 1-8 study

If a patient has already been on a higher dose of semaglutide, I may start tirzepatide at a slightly higher dose, as their body is already accustomed to medications in the incretin class and is therefore less likely to experience adverse effects

GLP1-S Mechanism of Action (Based on Research) GLP1-S is a GLP-1 receptor agonist, meaning it binds to and activates the same receptor as the natural incretin hormone GLP-1

It corresponds to a partial sequence derived from a protein found in gastric juice and is produced synthetically for laboratory use (ref

Oxidative stress has been repeatedly linked to the development of multiple different chronic diseases including diabetes, cancer and cardiovascular diseases